Key result
Individualized nOH treatment in Parkinson disease may reduce falls, cognitive impairment, and death.
Why the study?
Orthostatic hypotension is the primary manifestation of cardiovascular autonomic dysfunction in Parkinson disease and can be a prodromal feature, motivating a review of recent progress.
Accurate identification and individualized treatment of neurogenic orthostatic hypotension in Parkinson disease is crucial and may reduce the risk of falls, cognitive impairment, and death.
Supports screening in Parkinson disease; leaves open need for prospective trials to confirm benefit.
Purpose of the Review: Orthostatic hypotension (OH) is the primary manifestation of cardiovascular autonomic dysfunction in Parkinson disease (PD) and can be a prodromal feature of the disease. We review the recent progress in the field of autonomic dysfunction in PD. Recent Findings: Individuals with isolated neurogenic OH should be followed up frequently because they may evolve into PD, dementia with Lewy bodies, or multiple system atrophy. The prevalence of OH in PD increases with disease stages, but the role of levodopa remains unclear. Measurement of supine and standing heart rate and blood pressure allows for accurate identification of neurogenic OH in the clinic. Summary: Accurate identification of neurogenic OH in the clinic is crucial for identification of individuals who may benefit from participation in neuroprotective trials in the future. The treatment of OH in PD should be individualized and may reduce the risk of falls, cognitive impairment, and death.
No takes yet. Share an insight, caveat, or question.
Lamotte et al. (2022) conducted a review in Orthostatic hypotension in Parkinson disease. Accurate identification and individualized treatment of neurogenic orthostatic hypotension in Parkinson disease may reduce the risk of falls, cognitive impairment, and death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: